Lupin Limited has informed the stock exchanges that its Ankleshwar manufacturing facility in India has received a Form-483 from the U.S. FDA following a recent inspection. The pharmaceutical company disclosed this development in a regulatory filing dated March 07, 2026.

FDA Inspection Details

The U.S. FDA inspection at the Ankleshwar facility was conducted over a five-day period and concluded with specific regulatory observations.

Company Response and Commitment

Lupin has outlined its approach to addressing the FDA's findings and maintaining regulatory compliance. The company stated it will respond to the U.S. FDA within the stipulated timeframe to address the observations noted during the inspection.

The pharmaceutical manufacturer emphasized its commitment to maintaining Current Good Manufacturing Practice (CGMP) standards across all its facilities. This commitment reflects the company's focus on ensuring regulatory compliance and quality standards in its manufacturing operations.

Regulatory Disclosure

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer, and sent to both the National Stock Exchange of India Limited and BSE Limited.

Form-483 observations are issued by the FDA when inspectors identify conditions that may constitute violations of FDA regulations during facility inspections. Companies typically have a specified timeframe to respond with corrective actions and preventive measures.

Lupin Limited has informed stock exchanges about a timeline extension for its subsidiary's acquisition of VISUfarma B.V., a Netherlands-based company. The pharmaceutical company communicated this update through a regulatory filing dated February 27, 2026.

Transaction Details

The acquisition involves Nanomi B.V., Lupin's wholly owned subsidiary in the Netherlands, acquiring the entire share capital of VISUfarma B.V. The company had previously communicated about this transaction through intimations dated September 29, 2025 and December 30, 2025.

Timeline Extension and Pending Approvals

The transaction, which was originally expected to be completed by February 28, 2026, is now anticipated to be completed in April 2026. The extension is attributed to the pending satisfaction of specific closing conditions that are required for the transaction completion. The deal delay reflects the complex nature of cross-border acquisitions where regulatory approvals and other conditions precedent need to be satisfied before transaction closure.

Regulatory Compliance

The update was communicated to both the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer of Lupin Limited.

The company stated that the proposed transaction is still ongoing and emphasized that the completion remains subject to fulfillment of specified closing conditions. This represents a standard approach in cross-border acquisitions where regulatory approvals and other conditions precedent need to be satisfied before transaction closure.